Coherus Oncology (CHRS) Notes Payables (2013 - 2021)
Coherus Oncology's (CHRS) quarterly Notes Payables came in at $81.0 million in Q3 2021, little changed quarter-over-quarter from $80.6 million in Q2 2021.
Coherus Oncology (CHRS) Notes Payables (2013 - 2021) Analysis & Trends
Coherus Oncology has disclosed Notes Payables across 2 years of filings, most recently posting $81.0 million for Q3 2021.
- Notes Payables for Q3 2021 came in at $81.0 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2021 was $81.0 million (changed N/A YoY), and the FY2013 annual result was $1.1 million, changed N/A from the prior year.
- Notes Payables came in at $81.0 million for Q3 2021 at Coherus Oncology, roughly flat from $80.6 million in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $81.0 million in Q3 2021 to a low of $80.2 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Coherus Oncology | 199.14 Mn | 32.09 Mn | 8.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 80.98 Mn |
| Jun 30, 2021 | 80.61 Mn |
| Mar 31, 2021 | 80.24 Mn |
| Dec 31, 2013 | 1.11 Mn |